Renin-angiotensin system inhibitors (CONSENSUS trial), particularly angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), and angiotensin receptor-neprilysin inhibitors (ARNIs), form the cornerstone of HF therapy [12]. This evidence concerns the gene REN and hydrops fetalis.